Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$19.71 - $24.57 $19.2 Million - $23.9 Million
973,057 New
973,057 $23.2 Million
Q4 2022

Feb 14, 2023

BUY
$20.64 - $26.24 $7.64 Million - $9.72 Million
370,294 New
370,294 $9.42 Million

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $740M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Iron Triangle Partners LP Portfolio

Follow Iron Triangle Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Iron Triangle Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Iron Triangle Partners LP with notifications on news.